Lumigan 0.01%

Reduction of elevated IOP in patients w/ open-angle glaucoma or ocular HTN.

1 drop in the affected eye(s) once daily in the evening.

Hypersensitivity.

Increased pigmentation of iris, periorbital tissue (eyelid) & eyelashes. Potential for permanent increased brown iris pigmentation; hair growth in skin areas in contact repeatedly w/ soln. Patients w/ active intraocular inflammation (eg, uveitis); inflammatory ocular conditions eg, neovascular, inflammatory, angle-closure, congenital or narrow-angle glaucoma. Risk of developing bacterial keratitis in patients w/ disrupted ocular epithelial surface. Macular edema including cystoid macular edema. Aphakic, pseudophakic patients w/ torn posterior lens capsule, or known risk factors for macular edema (eg, intraocular surgery, retinal vein occlusions, ocular inflammatory disease & diabetic retinopathy). May decrease IOP-lowering effect w/ frequent exposure of >1 dose daily. Regularly examine patients who develop increased iris pigmentation. Inform patient of possibility of eyelash growth before treatment. Remove contact lens prior to administration & reinsert 15 min after. Monitor changes in IOP for patients in concomitant use w/ other prostaglandin analogs. May affect ability to drive & operate machine. Moderate to severe hepatic impairment. Renal impairment. Pregnancy & lactation. Not recommended in childn or adolescents/ped patients <16 yr.

Ocular/conjunctival hyperemia. Eye irritation & pruritus, eyelid erythema & pruritus, eyelash growth, punctate keratitis; hypertrichosis, skin hyperpigmentation; instillation site irritation.

Potential for reduced IOP-lowering effect w/ other prostaglandin analogs.

Antiglaucoma Preparations

S01EE03 - bimatoprost ; Belongs to the class of prostaglandin analogues. Used in the treatment of glaucoma and hypotrichosis of the eyelashes.

E-D